BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 10778959)

  • 1. A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer.
    Huan SD; Natale RB; Stewart DJ; Sartiano GP; Stella PJ; Roberts JD; Symes AL; Finizio M
    Clin Cancer Res; 2000 Apr; 6(4):1333-6. PubMed ID: 10778959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
    Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
    J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer.
    Ansari MS; Gupta NP
    Urol Oncol; 2004; 22(5):415-20. PubMed ID: 15464923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
    Borden LS; Clark PE; Lovato J; Hall MC; Stindt D; Harmon M; M Mohler R; Torti FM
    Cancer; 2006 Sep; 107(5):1093-100. PubMed ID: 16888761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
    Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
    Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
    Lin CC; Hsu CH; Chen J; Tsai TC; Cheng AL; Pu YS
    Anticancer Res; 2001; 21(2B):1385-90. PubMed ID: 11396219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
    Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
    Heidenreich A; Sommer F; Ohlmann CH; Schrader AJ; Olbert P; Goecke J; Engelmann UH
    Cancer; 2004 Sep; 101(5):948-56. PubMed ID: 15329902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer.
    Ko YJ; Small EJ; Kabbinavar F; Chachoua A; Taneja S; Reese D; DePaoli A; Hannah A; Balk SP; Bubley GJ
    Clin Cancer Res; 2001 Apr; 7(4):800-5. PubMed ID: 11309325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrazoloacridine for the treatment of hormone-refractory prostate cancer.
    Small EJ; Fippin LJ; Whisenant SP
    Cancer Invest; 1998; 16(7):456-61. PubMed ID: 9774952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
    Picus J; Schultz M
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group.
    Moore MM; Stockler M; Lim R; Mok TS; Millward M; Boyer MJ
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):845-50. PubMed ID: 20082080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer.
    Turner SL; Gruenewald S; Spry N; Gebski V;
    Br J Cancer; 2001 Feb; 84(3):297-302. PubMed ID: 11161391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.
    Amin A; Halabi S; Gelmann EP; Stadler W; Vogelzang N; Small E
    Urol Oncol; 2004; 22(5):398-403. PubMed ID: 15464920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity.
    Miglietta L; Cannobbio L; Boccardo F
    Anticancer Res; 1995; 15(6B):2825-8. PubMed ID: 8669872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma.
    Bhandari MS; Pienta KJ; Fardig J; Olson K; Smith DC
    Cancer; 2006 Apr; 106(8):1715-21. PubMed ID: 16534795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer.
    Borrega P; Velasco A; Bolaños M; del Mar Perez M; Mel JR; Reina JJ; Rodríguez-Jaraiz MA; Chaves M; González-Barón M
    Urol Oncol; 2004; 22(1):32-5. PubMed ID: 14969801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
    Vogelzang NJ; Karrison T; Stadler WM; Garcia J; Cohn H; Kugler J; Troeger T; Giannone L; Arrieta R; Ratain MJ; Vokes EE
    Cancer; 2004 Jan; 100(1):65-71. PubMed ID: 14692025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma.
    Daliani DD; Assikis V; Tu SM; Papandreou CN; Pagliaro LC; Holtkamp T; Wang X; Thall PF; Logothetis CJ
    Cancer; 2003 Feb; 97(3):561-7. PubMed ID: 12548597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.